Cargando…
Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort
Ovarian cancer remains the most lethal gynaecological malignancy, as its timely detection at early stages remains elusive. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy of biofluids has been previously applied in pilot studies for ovarian cancer diagnosis, with promi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405472/ https://www.ncbi.nlm.nih.gov/pubmed/34195877 http://dx.doi.org/10.1007/s00216-021-03472-8 |
_version_ | 1783746341516607488 |
---|---|
author | Giamougiannis, Panagiotis Morais, Camilo L. M. Rodriguez, Brice Wood, Nicholas J. Martin-Hirsch, Pierre L. Martin, Francis L. |
author_facet | Giamougiannis, Panagiotis Morais, Camilo L. M. Rodriguez, Brice Wood, Nicholas J. Martin-Hirsch, Pierre L. Martin, Francis L. |
author_sort | Giamougiannis, Panagiotis |
collection | PubMed |
description | Ovarian cancer remains the most lethal gynaecological malignancy, as its timely detection at early stages remains elusive. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy of biofluids has been previously applied in pilot studies for ovarian cancer diagnosis, with promising results. Herein, these initial findings were further investigated by application of ATR-FTIR spectroscopy in a large patient cohort. Spectra were obtained by measurements of blood plasma and serum, as well as urine, from 116 patients with ovarian cancer and 307 patients with benign gynaecological conditions. A preliminary chemometric analysis revealed significant spectral differences in ovarian cancer patients without previous chemotherapy (n = 71) and those who had received neo-adjuvant chemotherapy—NACT (n = 45), so these groups were compared separately with benign controls. Classification algorithms with blind predictive model validation demonstrated that serum was the best biofluid, achieving 76% sensitivity and 98% specificity for ovarian cancer detection, whereas urine exhibited poor performance. A drop in sensitivities for the NACT ovarian cancer group in plasma and serum indicates the potential of ATR-FTIR spectroscopy to identify chemotherapy-related spectral changes. Comparisons of regression coefficient plots for identification of biomarkers suggest that glycoproteins (such as CA125) are the main classifiers for ovarian cancer detection and responsible for smaller differences in spectra between NACT patients and benign controls. This study confirms the capacity of biofluids’ ATR-FTIR spectroscopy (mainly blood serum) to diagnose ovarian cancer with high accuracy and demonstrates its potential in monitoring response to chemotherapy, which is reported for the first time. GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00216-021-03472-8. |
format | Online Article Text |
id | pubmed-8405472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-84054722021-09-09 Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort Giamougiannis, Panagiotis Morais, Camilo L. M. Rodriguez, Brice Wood, Nicholas J. Martin-Hirsch, Pierre L. Martin, Francis L. Anal Bioanal Chem Research Paper Ovarian cancer remains the most lethal gynaecological malignancy, as its timely detection at early stages remains elusive. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy of biofluids has been previously applied in pilot studies for ovarian cancer diagnosis, with promising results. Herein, these initial findings were further investigated by application of ATR-FTIR spectroscopy in a large patient cohort. Spectra were obtained by measurements of blood plasma and serum, as well as urine, from 116 patients with ovarian cancer and 307 patients with benign gynaecological conditions. A preliminary chemometric analysis revealed significant spectral differences in ovarian cancer patients without previous chemotherapy (n = 71) and those who had received neo-adjuvant chemotherapy—NACT (n = 45), so these groups were compared separately with benign controls. Classification algorithms with blind predictive model validation demonstrated that serum was the best biofluid, achieving 76% sensitivity and 98% specificity for ovarian cancer detection, whereas urine exhibited poor performance. A drop in sensitivities for the NACT ovarian cancer group in plasma and serum indicates the potential of ATR-FTIR spectroscopy to identify chemotherapy-related spectral changes. Comparisons of regression coefficient plots for identification of biomarkers suggest that glycoproteins (such as CA125) are the main classifiers for ovarian cancer detection and responsible for smaller differences in spectra between NACT patients and benign controls. This study confirms the capacity of biofluids’ ATR-FTIR spectroscopy (mainly blood serum) to diagnose ovarian cancer with high accuracy and demonstrates its potential in monitoring response to chemotherapy, which is reported for the first time. GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00216-021-03472-8. Springer Berlin Heidelberg 2021-07-01 2021 /pmc/articles/PMC8405472/ /pubmed/34195877 http://dx.doi.org/10.1007/s00216-021-03472-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Paper Giamougiannis, Panagiotis Morais, Camilo L. M. Rodriguez, Brice Wood, Nicholas J. Martin-Hirsch, Pierre L. Martin, Francis L. Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
title | Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
title_full | Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
title_fullStr | Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
title_full_unstemmed | Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
title_short | Detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via ATR-FTIR spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
title_sort | detection of ovarian cancer (± neo-adjuvant chemotherapy effects) via atr-ftir spectroscopy: comparative analysis of blood and urine biofluids in a large patient cohort |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405472/ https://www.ncbi.nlm.nih.gov/pubmed/34195877 http://dx.doi.org/10.1007/s00216-021-03472-8 |
work_keys_str_mv | AT giamougiannispanagiotis detectionofovariancancerneoadjuvantchemotherapyeffectsviaatrftirspectroscopycomparativeanalysisofbloodandurinebiofluidsinalargepatientcohort AT moraiscamilolm detectionofovariancancerneoadjuvantchemotherapyeffectsviaatrftirspectroscopycomparativeanalysisofbloodandurinebiofluidsinalargepatientcohort AT rodriguezbrice detectionofovariancancerneoadjuvantchemotherapyeffectsviaatrftirspectroscopycomparativeanalysisofbloodandurinebiofluidsinalargepatientcohort AT woodnicholasj detectionofovariancancerneoadjuvantchemotherapyeffectsviaatrftirspectroscopycomparativeanalysisofbloodandurinebiofluidsinalargepatientcohort AT martinhirschpierrel detectionofovariancancerneoadjuvantchemotherapyeffectsviaatrftirspectroscopycomparativeanalysisofbloodandurinebiofluidsinalargepatientcohort AT martinfrancisl detectionofovariancancerneoadjuvantchemotherapyeffectsviaatrftirspectroscopycomparativeanalysisofbloodandurinebiofluidsinalargepatientcohort |